Drug resistance is a major hurdle in cancer treatment and a key cause of poor prognosis.Epitranscriptomics and epiproteomics are crucial in cell proliferation,migration,invasion,and epithelial–mesenchymal transition....Drug resistance is a major hurdle in cancer treatment and a key cause of poor prognosis.Epitranscriptomics and epiproteomics are crucial in cell proliferation,migration,invasion,and epithelial–mesenchymal transition.In recent years,epitranscriptomic and epiproteomic modification has been investigated on their roles in overcoming drug resistance.In this review article,we summarized the recent progress in overcoming cancer drug resistance in three novel aspects:(i)mRNA modification,which includes alternative splicing,A-to-I modification and mRNA methylation;(ii)noncoding RNAs modification,which involves miRNAs,lncRNAs,and circRNAs;and(iii)posttranslational modification on molecules encompasses drug inactivation/efflux,drug target modifications,DNA damage repair,cell death resistance,EMT,and metastasis.In addition,we discussed the therapeutic implications of targeting some classical chemotherapeutic drugs such as cisplatin,5-fluorouridine,and gefitinib via these modifications.Taken together,this review highlights the importance of epitranscriptomic and epiproteomic modification in cancer drug resistance and provides new insights on potential therapeutic targets to reverse cancer drug resistance.展开更多
基金supported by grants from the Guangdong Basic and Applied Basic Research fund project(2019B1515120033)the Science and Technology Foundation of Shenzhen(JCYJ20180305164128430)+2 种基金the International Cooperation Foundation of Shenzhen(GJHZ20180928171602104)the Shenzhen Economic and Information Committee“Innovation Chain and Industry Chain”integration special support plan project(20180225112449943)the Shenzhen Public Service Platform on Tumor Precision Medicine and Molecular Diagnosis.
文摘Drug resistance is a major hurdle in cancer treatment and a key cause of poor prognosis.Epitranscriptomics and epiproteomics are crucial in cell proliferation,migration,invasion,and epithelial–mesenchymal transition.In recent years,epitranscriptomic and epiproteomic modification has been investigated on their roles in overcoming drug resistance.In this review article,we summarized the recent progress in overcoming cancer drug resistance in three novel aspects:(i)mRNA modification,which includes alternative splicing,A-to-I modification and mRNA methylation;(ii)noncoding RNAs modification,which involves miRNAs,lncRNAs,and circRNAs;and(iii)posttranslational modification on molecules encompasses drug inactivation/efflux,drug target modifications,DNA damage repair,cell death resistance,EMT,and metastasis.In addition,we discussed the therapeutic implications of targeting some classical chemotherapeutic drugs such as cisplatin,5-fluorouridine,and gefitinib via these modifications.Taken together,this review highlights the importance of epitranscriptomic and epiproteomic modification in cancer drug resistance and provides new insights on potential therapeutic targets to reverse cancer drug resistance.
